Fulgent Genetics, Inc. FLGT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $320.35M+9.5% | $322.67M+13.8% | $315.55M+13.6% | $303.22M+4.3% | $292.45M+1.7% | ||
| $196.33M+9.7% | $191.8M+8.8% | $185.41M+4.7% | $181.82M+2.7% | $178.99M-0.4% | ||
| $124.02M+9.3% | $130.88M+22.1% | $130.14M+29.4% | $121.4M+6.8% | $113.46M+5.3% | ||
| 38.7%-0.1pp | 40.6%+2.7pp | 41.2%+5.0pp | 40%+0.9pp | 38.8%+1.3pp | ||
| $55.69M+11.9% | $53.91M+10.4% | $51.85M+6.6% | $49.77M+6.2% | $49.78M+15.5% | ||
| $47.13M+31.9% | $43.37M+19.7% | $41.93M+12.7% | $39.41M+3.1% | $35.72M-11.5% | ||
| $119.06M+29.5% | $116.66M+32.4% | $99.36M+4.1% | $96.97M+5.4% | $91.91M+3.6% | ||
| $8.07M+1.3% | $8.03M+0.8% | $8M+0.8% | $7.97M+0.9% | $7.97M+1.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $229.94M+24.0% | $221.97M+22.5% | $201.14M-35.0% | $194.12M-36.4% | $185.37M-38.3% | ||
| $229.94M+24.0% | $221.97M+22.5% | $201.14M-35.0% | $194.12M-36.4% | $185.37M-38.3% | ||
| -$105.92M-47.3% | -$91.1M-23.2% | -$70.99M+66.0% | -$72.72M+62.0% | -$71.92M+62.6% | ||
| -33.1%-8.5pp | -28.2%-2.2pp | -22.5%+52.7pp | -24%+41.9pp | -24.6%+42.4pp | ||
| $78K— | $75K— | —— | —— | —— | ||
| $31.55M-1.2% | $30.92M-1.2% | $32.11M+10.7% | $32.32M+18.1% | $31.94M+29.0% | ||
| $21.64M-3.4% | $21.07M-4.0% | $22.2M+12.2% | $12.9M-53.7% | $22.4M— | ||
| -$84.28M-70.2% | -$70.03M-34.8% | -$48.8M+74.2% | -$59.82M+63.5% | -$49.51M+70.4% | ||
| -$9.27M-21.4% | -$8.39M-3.1% | -$4.63M— | -$7.78M— | -$7.64M— | ||
| -$73.81M-81.0% | -$60.51M-41.7% | -$42.98M+73.9% | -$51.02M+68.8% | -$40.78M+75.4% | ||
| -23%-9.1pp | -18.8%-3.7pp | -13.6%+45.8pp | -16.8%+39.4pp | -13.9%+43.8pp | ||
| -$2.39-79.7% | -$1.96-39.0% | -$1.39+74.8% | -$1.66+69.7% | -$1.33+76.1% | ||
| -$2.39-79.7% | -$1.96-39.0% | -$1.39+74.8% | -$1.66+69.7% | -$1.33+76.1% | ||
| 123M+1.1% | 122.9M+2.0% | 122.4M+1.9% | 122M+2.0% | 121.6M+1.8% | ||
| 123M+1.1% | 122.9M+2.0% | 122.4M+1.9% | 122M+2.0% | 121.6M+1.8% | ||
| -$2.39-79.7% | -$1.96-39.0% | -$1.39+74.8% | -$1.66+69.7% | -$1.33+76.1% | ||
| -$2.39-79.7% | -$1.96-39.0% | -$1.39+74.8% | -$1.66+69.7% | -$1.33+76.1% | ||
| $8.07M+1.3% | $8.03M+0.8% | $8M+0.8% | $7.97M+0.9% | $7.97M+1.2% | ||
| -$2.2M+33.5% | -$1.21M+67.5% | -$1.47M+48.6% | -$2.97M-116% | -$3.31M-121% | ||
| $351K-35.6% | $399K-26.7% | $447K-18.1% | $494K-8.5% | $545K-13.9% | ||
| —— | —— | —— | —— | -$146K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $800K— | $550K— | —— | —— | —— | ||
| —— | —— | —— | $27.69M— | $22.31M— | ||
| $14.27M— | $8.91M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.03M— | ||
| -$48.45M-267% | -$14.79M-205% | -$14.58M+52.1% | -$14.7M+57.2% | -$13.21M+73.3% | ||
| $94.58M— | $111.37M— | $72.76M— | —— | —— | ||
| —— | —— | —— | -$25.09M-168% | $9.36M-77.8% | ||
| —— | —— | -$13K— | -$31K— | —— | ||
| $95K-84.9% | $153K-72.3% | $116K— | $665K— | $630K— | ||
| —— | —— | —— | —— | —— | ||
| $5.35M+72.3% | $3.04M+4.7% | $2.83M-24.9% | $2.91M-24.7% | $3.1M-12.4% | ||
| —— | —— | —— | —— | $0-100% | ||
| $23.06M-43.7% | $22.57M-44.0% | $21.37M-46.1% | $34.86M+39.3% | $40.98M+69.1% | ||
| —— | —— | —— | —— | $57K-93.2% | ||
| —— | —— | —— | —— | $38.25K+155% | ||
| $6.76M— | $7.65M— | —— | —— | —— | ||
| $320.35M+9.5% | $322.67M+13.8% | $315.55M+13.6% | $303.22M+4.3% | $292.45M+1.7% | ||
| $38.92M-10.6% | $39.58M-11.0% | $40.71M-10.5% | $41.92M-7.8% | $43.51M-1.5% | ||
| -$105.92M-47.3% | -$91.1M-23.2% | -$70.99M+66.0% | -$72.72M+62.0% | -$71.92M+62.6% | ||
| -$81.72M-71.2% | -$66.97M-36.7% | -$46.79M+74.5% | -$48.64M+70.7% | -$47.73M+71.3% | ||
| -$81.72M-71.2% | -$66.97M-36.7% | -$46.79M+74.5% | -$48.64M+70.7% | -$47.73M+71.3% | ||
| -25.5%-9.2pp | -20.8%-3.5pp | -14.8%+51.3pp | -16%+41.0pp | -16.3%+41.6pp | ||
| -$105.92M-47.3% | -$91.1M-23.2% | -$70.99M+66.0% | -$72.72M+62.0% | -$71.92M+62.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Fulgent Genetics, Inc.'s revenue?
- Fulgent Genetics, Inc. (FLGT) generated $320.3M in revenue over the trailing twelve months, up 9.5% year over year.
- Is Fulgent Genetics, Inc. profitable?
- Fulgent Genetics, Inc. is not currently profitable: it reported a net loss of $73.8M over the trailing twelve months, a -23.0% net margin.
- What are Fulgent Genetics, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is -33.1%, with a -23.0% net margin.
- What is Fulgent Genetics, Inc.'s earnings per share?
- Fulgent Genetics, Inc.'s diluted EPS over the trailing twelve months is $-2.39.
- Where does Fulgent Genetics, Inc.'s income statement data come from?
- Every line is extracted from Fulgent Genetics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
